Clinical Trial Categories
  • Age & Physical Activity (1)
  • Alzheimer's Disease (7)
  • Arthritis (3)
  • Asthma (1)
  • Cancer - Bladder (1)
  • Cancer - Brain & CNS (16)
  • Cancer - Breast (8)
  • Cancer - Colon/Colorectal (2)
  • Cancer - Digestive System (2)
  • Cancer - Female Reproductive (8)
  • Cancer - Gastric (1)
  • Cancer - Kidney (2)
  • Cancer - Leukemia (6)
  • Cancer - Liver (1)
  • Cancer - Lung (3)
  • Cancer - Lymphoma (27)
  • Cancer - Melanoma (15)
  • Cancer - Mesothelioma (2)
  • Cancer - Myeloma (10)
  • Cancer - Other (5)
  • Cancer - Ovarian (2)
  • Cancer - Pancreas (2)
  • Cancer - Peritoneal (5)
  • Cancer - Prostate (12)
  • Cancer - Sarcoma (1)
  • Cancer - Stomach (1)
  • Cancer - Testicular (1)
  • Cancer - Tissue (6)
  • Crohn's Disease (3)
  • Dermatitis (2)
  • Dermatomyositis (1)
  • Healthy (6)
  • Hepatitis C (2)
  • HIV (4)
  • HPV (1)
  • Hypercholesterolemia (1)
  • Immune Disease - Autoimmune (9)
  • Immune Disease - Primary (2)
  • Immune Disease - Secondary (6)
  • Infectious Disease (2)
  • Inflammatory Disease (3)
  • Kidney Transplant (1)
  • Liver Disease (2)
  • Lupus Erythematosus (3)
  • Multiple Sclerosis (3)
  • Neurodegenerative (1)
  • OX40 (1)
  • Parkinson's Disease (1)
  • Pediatric (3)
  • Transplant (2)

KLH in Clinical Trials

Clinical trials involving KLH. Details such as study status, design and investigators are available by link to outside sites.

Clinical trial links are intended for informational purposes only, and are not solicitations for any study nor provided for the purposes of giving medical advice. See Terms of Use for this site.

(in order by date)

Entries in Adjuvant Oil / Surfactant (2)

Thursday
Dec012011

NCT01489956

A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH)

Conditions: Autoimmune Disorders
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID) 
Phase 0 completed

Tuesday
Sep072004

NCT00091143

Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma

Conditions: Melanoma
Sponsors: Providence Cancer Center, Earle A. Chiles Research Institute|National Cancer Institute (NCI)
Phase I